Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2352W HIGH $2.75
Volume
1.26 M
Value Traded
2.26 M
Short % Float
6.5%
+15.95%Week
-3.46%1 Month
+69.69%3 Month
-1.4%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.91 M
EPS (TTM)
-0.65
P/E Ratio
-
Ent. Value
8.23 M
Total Shares
19.46 M
Float Shares
18.54 M
Insiders
4.72%
Institutions
4.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ENSC Catalyst Timeline
Dated clinical, regulatory and corporate events for Ensysce Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ensysce Biosciences, Inc.
232Total events
17Upcoming
34Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Trial Authorization (CTA / IND)CY200Ex-US Regulatory
Phase 2a protocol for CY200 submitted to UK MHRA
Complex Regional Pain Syndrome Type 1source ↗
▲Oral PresentationPresentation
CMO Richard Langford selected to present at FDA public hearing on psychedelic drugs
●R&D DayPresentation
Ensysce hosted CRPS symposium at PainWeek 2026
Complex Regional Pain Syndromesource ↗
▲Enrollment CompletePF614Trial
Enrollment completed in final stage (Part 3) of PF614-MPAR-102 study
painsource ↗
▼Equity OfferingCorporate
Private placement financing initial close expected to raise $21.5 million
◆Oral PresentationPresentation
CPDD 88th Annual Meeting presentation by Dr. Lynn Kirkpatrick
substance use disorderssource ↗
◆Oral PresentationPresentation
Commercial Excellence and AI - Immersion Lab discussions by Mr. Geoff Birkett
pain therapeuticssource ↗
◆Oral PresentationPF614Presentation
European Pain Therapeutics Summit presentation on PF614 and PF614-MPAR by Dr. Lynn Kirkpatrick
painsource ↗
◆Oral PresentationPF614Presentation
European Pain Therapeutics Summit presentation on PF614 and PF614-MPAR by Dr. Lynn Kirkpatrick
painsource ↗
▼Equity OfferingCorporate
Closed second tranche of $2 million convertible preferred stock financing
◆Oral PresentationPresentation
USASP Annual Scientific Meeting presentation by Dr. William Schmidt
pain therapeuticssource ↗
▲PublicationPF614Presentation
First peer-reviewed clinical manuscript on MPAR overdose protection published in Journal of Opioid Management
painsource ↗
◆Pipeline PrioritizationCorporate
Board initiates formal review of strategic alternatives to enhance shareholder value
▲Enrollment MilestonePF614Trial
Enrolled 50% of subjects targeted for interim review in pivotal Phase 3 trial
moderate to severe pain following abdominoplastysource ↗
▲PublicationPF614Presentation
First peer-reviewed clinical publication of PF614-MPAR in Journal of Opioid Management
painsource ↗
▲Enrollment MilestonePF614Trial
Enrolled 50% of subjects targeted for interim review in PF614-301 Phase 3 trial
moderate to severe painsource ↗
▲Patent GrantedPF8026IP / Competition
Notice of Allowance from European Patent Office for patent covering PF8026
ADHDsource ↗
▲Patent GrantedIP / Competition
U.S. Patent Office issues Notice of Allowance for MPAR technology patent covering composition-of-matter and method-of-use claims, extending protection through 2042
▲Trial InitiationPF614Trial
Enrollment began in pivotal Phase 3 trial
moderate to severe pain following abdominoplastysource ↗
▲First Patient DosedPF614Trial
First patient enrolled in Phase 3 trial PF614-301 for PF614
moderate-to-severe post-surgical painsource ↗
▲Patent GrantedIP / Competition
USPTO allowed new patent covering MPAR technology (composition-of-matter and method-of-use) expiring 2042
▲Patent GrantedPF8026IP / Competition
European patent office provided notice of allowance for patent covering PF8026 (TAAP and MPAR technologies)
▼Equity OfferingCorporate
Closed $4 million convertible preferred stock financing with potential additional $16 million over 24 months
▲FDA Feedback ReceivedPF614FDA Meeting
FDA provided encouraging feedback on PF614-MPAR development pathway including support for 505(b)(2) pathway
opioid overdose protectionsource ↗
▼Equity OfferingCorporate
Convertible preferred stock offering with gross proceeds of $4 million
▲Trial InitiationPF614Trial
Initiation of pivotal Phase 3 PF614-301 trial
moderate to severe post-surgical painsource ↗
▲FDA Feedback ReceivedPF614FDA Meeting
FDA feedback supporting overdose protection labeling and 505(b)(2) pathway
severe pain with overdose protectionsource ↗
▼Equity OfferingCorporate
Issuance of new unregistered warrants in concurrent private placement
▲Enrollment CompletePF614Trial
Part 1 of PF614-MPAR-102 study completed enrollment
severe painsource ↗
▲Patent GrantedPF9001IP / Competition
Notice of Allowance from USPTO for patent covering PF9001
opioid use disordersource ↗
◆Trial InitiationPF614Trial
Initiation of PF614-301 trial expected mid-year 2025
moderate to severe painsource ↗
Past FDA Catalysts and PDUFA Decisions
How ENSC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | PF614-MPAR | Phase 1b interim results | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Ensysce Biosciences, Inc. faces pipeline headwinds (33/100), with $226M risk-adjusted pipeline value, led by PF614 in Acute Pain (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PF614 Small moleculeNCT06602271 | Postoperative Pain, Acute | Phase 3 | RECRUITING | 320 | Nov 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ENSC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PF614-MPAR BreakthroughFast Track | opioid overdose protection | Phase 1 | 2026-03-03 | PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered.Read More | Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) TechnologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GOWER BOB GDirector | Buy | 400,000 916,740 held | $0.50 | 08/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ENSC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 25.00 K | 86.67 K |
ENSC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENSC ranks across every disease it competes in
Competitive Position is a premium feature
See how ENSC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENSC News
ENSCEnsysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
Ensysce Biosciences has submitted the protocol for a Phase 2a clinical study of CY200, aimed at treating Complex Regional Pain Syndrome (CRPS). This submission to the UK MHRA is a significant milestone in the development of CY200, which is designed to evaluate its efficacy and safety compared to placebo. The study seeks to address the urgent need for effective treatments for CRPS, a condition that severely impacts patients' quality of life.
Read more →ENSC▼ -6.2%on this news
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Ensysce Biosciences advanced its CRPS program at PainWeek 2026, showcasing its novel therapies aimed at chronic pain management. The company also participated in an FDA hearing on psychedelic drug regulation, emphasizing the importance of public input on treatment access and safety. CEO Lynn Kirkpatrick highlighted the promising potential of these therapies in addressing severe pain.
Read more →ENSCEnsysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Ensysce Biosciences announced that Dr. Richard Langford will speak at an FDA public hearing on the therapeutic use of psychedelic drugs. This event is part of a broader initiative to explore the potential of psychedelics in treating serious mental health conditions. Ensysce aims to develop novel therapies for Complex Regional Pain Syndrome and is committed to shaping the future of psychedelic medicine.
Read more →ENSC▲ +14.1%on this news
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
Ensysce Biosciences, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences and industry events, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company focuses on developing novel therapies for chronic pain and is actively involved in discussions regarding the therapeutic use of psychedelics. Ensysce's CEO encourages investors to schedule meetings during these events.
Read more →ENSCEnsysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences has completed enrollment in the final phase of its PF614-MPAR-102 clinical study, which focuses on a novel opioid designed to mitigate overdose risks. This study is part of a Breakthrough Therapy-designated program aimed at addressing the opioid crisis. The PF614-MPAR technology features a safety mechanism that limits overdose potential while providing therapeutic benefits. The company is also exploring additional therapeutic applications beyond pain management.
Read more →ENSCEnsysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
Ensysce Biosciences announced its participation in the PAINWeek 2026 symposium, showcasing innovative approaches to pain management, particularly for Complex Regional Pain Syndrome (CRPS). The symposium will highlight the company's neural reset strategy and novel safety technologies aimed at improving treatment efficacy and safety. Key leaders in pain medicine will discuss how these advancements could redefine pain treatment.
Read more →ENSC▲ +14.7%on this news
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Ensysce Biosciences reported its Q2 2026 financial results, highlighting the acquisition of Cy Biopharma and the addition of CY200 for Complex Regional Pain Syndrome. The company secured up to $77 million in funding to support clinical trials, including a Phase 2 trial for CY200. Despite a net loss increase, Ensysce continues to advance its opioid development programs.
Read more →ENSC▲ +44.8%on this news
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Ensysce Biosciences has acquired Cy Biopharma, a clinical-stage company focused on neuroplastogenic therapies for Complex Regional Pain Syndrome (CRPS). The acquisition includes up to $77 million in private financing to support the development of CY200, which has received FDA Orphan Drug Designation. This strategic move aims to address significant unmet medical needs in chronic pain management.
Read more →ENSC▲ +6.2%on this news
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Ensysce Biosciences has been awarded a $5.3 million installment from NIDA, completing a $15 million federal grant to advance its PF614-MPAR opioid technology. This funding will support the completion of clinical studies and long-term non-clinical studies necessary for a New Drug Application. PF614-MPAR is designed to enhance opioid safety by actively preventing overdose.
Read more →ENSC▲ +6.3%on this news
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences has enrolled its first patient in the final phase of the PF614-MPAR-102 clinical study, which evaluates a novel opioid designed to prevent overdose. This first-in-class therapy utilizes a unique mechanism to control opioid release, aiming to enhance patient safety. The study is backed by the National Institute on Drug Abuse and follows previous positive data from earlier trials.
Read more →ENSCEnsysce Biosciences Reports First Quarter 2026 Financial Results IRB Approval Secured for PF614-MPAR-102 Part 3 ~
Ensysce Biosciences reported significant operational progress for Q1 2026, including securing IRB approval for the final stage of its PF614-MPAR-102 study and achieving 50% enrollment in its pivotal Phase 3 trial. The company also published its first peer-reviewed data supporting its overdose protection technology in opioids. Additionally, Ensysce expanded its patent portfolio, enhancing its position in both opioid and ADHD markets. A formal review of strategic alternatives, including potential partnerships, is underway to accelerate the development of its therapeutic platforms.
Read more →ENSCEnsysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs ~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~
Ensysce Biosciences announced the closing of a second financing round of $2 million as part of a broader agreement worth up to $20 million. This funding will support its flagship analgesic programs focusing on developing tamper-proof and abuse-resistant pain management solutions. The company aims to revolutionize the treatment landscape for severe pain using its proprietary platforms. CEO Kirkpatrick emphasized the investor confidence and the need for transformative treatments in pain management.
Read more →ENSCEnsysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~
Ensysce Biosciences recently reported its financial results for Q4 and full year 2025, highlighting notable progress in clinical trials and regulatory engagement for PF614. The company initiated its Phase 3 trial and received supportive feedback from the FDA regarding its development pathway for PF614-MPAR. Despite facing increased operational losses, Ensysce has strengthened its intellectual property, expanded its pipeline, and improved overall financial stability. The firm continues to focus on developing safer opioid medications while addressing the challenge of opioid abuse.
Read more →ENSCEnsysce Biosciences Initiates Live “Ask Me Anything” (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences has launched a live 'Ask Me Anything' session to engage with stakeholders about its strategic plans and the PF614 program. CEO Dr. Lynn Kirkpatrick highlighted the program's commercial potential and the company's commitment to transparency. Key topics included the timeline for PF614-301 and efforts to mitigate regulatory risks. The session demonstrated strong community interest and provided insights into the company's future direction.
Read more →ENSC▼ -15%on this newsshared move
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Ensysce Biosciences has published the first peer-reviewed clinical study on its MPAR technology, which provides overdose protection for opioid users. The study, featured in the Journal of Opioid Management, highlights the effectiveness of PF614-MPAR in maintaining therapeutic opioid levels while preventing overdose. This innovation represents a significant advancement in pain management and opioid safety.
Read more →ENSCEnsysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences has initiated a review of strategic alternatives aimed at enhancing shareholder value and advancing its proprietary technologies. The review may include partnerships, licensing, and other corporate transactions. CEO Dr. Lynn Kirkpatrick emphasized the potential of their technologies to improve opioid safety. However, no specific outcomes or timelines have been established.
Read more →ENSC▼ -6.6%on this newsshared move
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences has been invited to participate in several upcoming scientific and industry events, where it will present its innovative pain therapeutics and discuss its TAAP and MPAR programs. Key executives will share insights on the company's approach to reducing opioid abuse and overdose risks. These engagements aim to enhance collaboration within the clinical and scientific communities.
Read more →ENSC▼ -8.7%on this news· ran to -23% by day 3
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences has announced that it has enrolled 50% of subjects for interim review in its pivotal Phase 3 trial of PF614, a next-generation opioid aimed at treating severe acute pain. The trial is being conducted across three U.S. sites and aims to evaluate PF614's efficacy and safety post-abdominoplasty. The drug incorporates built-in abuse protection to enhance patient safety.
Read more →ENSCEnsysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences has received a Notice of Allowance for a new patent covering its MPAR® overdose protection technology, extending patent protection through 2042. This technology, which has received Breakthrough Therapy Designation from the FDA, aims to mitigate the effects of opioid overdoses. Ensysce is also exploring its application for other drug classes, enhancing safety in pain management.
Read more →ENSCEnsysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs ~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~
Ensysce Biosciences, Inc. has announced the closing of a $4 million financing round, which could lead to an additional $16 million to support its Phase 3 clinical development of PF614, an analgesic aimed at treating severe pain. The funding reflects strong investor confidence in the company's innovative pain management solutions. Ensysce aims to disrupt the current analgesic market with unique tamper-proof opioids designed to reduce the risks of drug abuse and overdose. While the financial backing provides a pathway to market readiness within 18-24 months, there are inherent risks associated with clinical success and regulatory approvals.
Read more →About Ensysce Biosciences, Inc.
Headquarters7946 IVANHOE AVENUE, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next ENSC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime